# Predicting Response to Capecitabine in Women With Metastatic Breast Cancer

> **NCT00953537** · NA · COMPLETED · sponsor: **Centre Antoine Lacassagne** · enrollment: 303 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00953537
- **Lead sponsor:** Centre Antoine Lacassagne
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-01
- **Final completion:** 2011-02
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00953537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00953537, "Predicting Response to Capecitabine in Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00953537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*